HSBC Holdings
ARQT icon

HSBC Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

HSBC Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$432K Buy
+16,436
New +$383K ﹤0.01% 2349
2025
Q3 		– Sell
-10,057
Closed -$139K – 2709
2025
Q2 		$139K Sell
10,057
-7,701
-43% -$108K ﹤0.01% 2784
2025
Q1 		$271K Buy
17,758
+207
+1% +$2.92K ﹤0.01% 2437
2024
Q4 		$248K Buy
17,551
+4,719
+37% +$51.7K ﹤0.01% 2601
2024
Q3 		$120K Sell
12,832
-1,267
-9% -$12.5K ﹤0.01% 2764
2024
Q2 		$131K Sell
14,099
-492,187
-97% -$4.45M ﹤0.01% 2678
2024
Q1 		$5.01M Buy
506,286
+362,351
+252% +$2.7M ﹤0.01% 1098
2023
Q4 		$465K Hold
143,935
– – ﹤0.01% 2078
2023
Q3 		$764K Sell
143,935
-880
-0.6% -$7.48K ﹤0.01% 1811
2023
Q2 		$1.38M Buy
144,815
+23,280
+19% +$258K ﹤0.01% 1581
2023
Q1 		$1.34M Sell
121,535
-4,286
-3% -$62K ﹤0.01% 1661
2022
Q4 		$1.86M Sell
125,821
-4,903
-4% -$85.7K ﹤0.01% 1709
2022
Q3 		$2.5M Buy
130,724
+18,967
+17% +$430K ﹤0.01% 1463
2022
Q2 		$2.38M Buy
111,757
+19,769
+21% +$406K ﹤0.01% 1504
2022
Q1 		$1.77M Buy
91,988
+57,465
+166% +$972K ﹤0.01% 1664
2021
Q4 		$810K Buy
+34,523
New +$687K ﹤0.01% 2165
2021
Q1 		– Sell
-9,010
Closed -$255K – 2719
2020
Q4 		$255K Buy
+9,010
New +$221K ﹤0.01% 2677

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HSBC Holdings's ARQT Position: Q2 2026 in Review

HSBC Holdings opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 16,436 shares worth $432K. The stake represents ﹤0.01% of the portfolio and ranks #2349 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in ARQT as recently as Q2 2025.

HSBC Holdings first reported a position in ARQT in Q4 2020 and has held it in 17 quarters since. The position peaked at $5.01M in Q1 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • HSBC Holdings held 16,436 shares of Arcutis Biotherapeutics worth $432K as of Q2 2026.
  • Arcutis Biotherapeutics was a new HSBC Holdings position in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2349 holding.
  • HSBC Holdings first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 17 quarters since.
  • HSBC Holdings's Arcutis Biotherapeutics position peaked at $5.01M in Q1 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.